Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics' stock has experienced volatility and a decline in the past six months, with a 67.74% decrease as of April 27, 2026. Key events include net losses reported in earnings reports, clinical development updates regarding CAD-1005, varied analyst ratings, financial concerns about its ability to continue as a going concern, and share dilution.

Cadrenal Therapeutics is a clinical-stage biopharmaceutical company without revenue from commercialized products. Demand is driven by investor interest in its research and development progress, clinical trial milestones, and potential for future market entry, making traditional demand seasonality not applicable.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on addressing critical gaps in acute and chronic anticoagulation management. Its pipeline includes Tecarfarin, an oral vitamin K antagonist for chronic use; CAD-1005, a selective 12-LOX inhibitor in Phase 3 development for heparin-induced thrombocytopenia; and Frunexian, a Factor XIa inhibitor for acute care settings.

Cadrenal Therapeutics is headquartered in Ponte Vedra, Florida, United States. The company focuses on global market opportunities, indicated by orphan drug designations from the U.S. FDA and the European Medicines Agency.

Cadrenal Therapeutics' brand reputation is shaped by its clinical development progress and analyst perceptions. Positive aspects include clinical milestones, orphan drug designations, and analyst optimism. Challenges include financial instability, stock volatility, and AI-based "Sell" ratings.

Cadrenal Therapeutics has a mixed ownership structure. Institutional investors hold approximately 4.85% to 7.92% of the stock. Insiders hold a significant portion, ranging from approximately 15.80% to 43.98% of the company. Retail investors hold a considerable stake, estimated to be around 51.17% to 78.80% of the company's stock.